Context Therapeutics Inc. (CNTX)
NASDAQ: CNTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CNTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $14.70M
- EPS (TTM)
- -$0.46
- Dividend yield
- None
- 52-week range
- 0.153 – 3.62
- Day range
- 0.1575 – 0.1754
- Volume / Avg
- 1.11M / 1.42M
- Beta
- —
- Shares outstanding
- 91.88M
52-week range
CNTX stock today
Context Therapeutics (CNTX) closed at $0.16 on Nov 20, down 5.10% (-$0.0086), versus the S&P 500's 3.70% decline. Shares are 95.6% below their 52-week high of $3.62, set on Mar 16, 2026 and 4.6% above the 52-week low of $0.153, near the bottom of the past year's range. CNTX is down 89.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 85.3%.
Context Therapeutics has posted a net loss over the last twelve months (EPS of -$0.46), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Context Therapeutics
Company profileContext Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Martin A. Lehr
- Headquarters
- Philadelphia, PA
- Employees
- 15
- IPO year
- 2021
- Website
- contexttherapeutics.com
Financial highlights
Full financialsContext Therapeutics reported a net loss of $36.1 million, compared with a loss of $26.7 million a year earlier. Diluted earnings per share came in at -$0.38.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-36.12M | $-26.73M | $-23.96M | $-14.84M | $-10.46M |
| EPS (diluted) | $-0.38 | $-0.46 | $-1.50 | $-0.93 | $-3.69 |
Analyst forecast
ForecastConsensus (10 analysts)
none
Avg. price target
$4.03+2418.75%
- Strong buy 3
- Buy 6
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $-0.08 vs $-0.09
- Surprise
- +11.11%
CNTX news
All CNTX newsContext Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NCELNewcelX Ltd. | 2.54 | -5.58% | $14.67M | vs CNTX |
| CELUCelularity Inc. Class A | 0.463 | -1.05% | $15.02M | vs CNTX |
| CTXRCitius Pharmaceuticals Inc. | 0.5085 | +2.27% | $13.96M | vs CNTX |
| BYSIBeyondSpring Inc. | 0.33 | -24.49% | $13.66M | vs CNTX |
| QNRXQuoin Pharmaceuticals Ltd. ADR | 3.28 | -2.35% | $15.76M | vs CNTX |
| PBMPsyence Biomedical Ltd. | 2.97 | +3.85% | $15.80M | vs CNTX |
| ACTUActuate Therapeutics Inc. | 0.2253 | +5.38% | $13.60M | vs CNTX |
| ATOSAtossa Therapeutics Inc. | 1.60 | -8.86% | $15.92M | vs CNTX |
Indexes, lists and sector
Context Therapeutics stock FAQ
What is Context Therapeutics's stock price today?
CNTX last traded at $0.16 as of Nov 20, 4:00 PM EST, down 5.10% on the day. Prices are delayed at least 15 minutes.
Who is Context Therapeutics's CEO?
Mr. Martin A. Lehr is the chief executive officer of Context Therapeutics Inc., which has about 15 employees.
What is the CNTX 52-week high?
The 52-week high for CNTX is $3.62 and the 52-week low is $0.153. The stock is currently 95.6% below its high.